NEW YORK – Twist Bioscience and Centogene announced on Wednesday a collaboration to develop and commercialize sequencing assay kits for rare disease genetic testing.
The assays will combine Centogene's experience in rare disease diagnostics with Twist's target enrichment capabilities for next-generation sequencing library preparation. The partners will design multiple tests and will attempt to make genetic testing more accessible to patients.
Financial and other details were not disclosed.
"Not only will this help to provide patients with quicker and more comprehensive answers today, but it will generate insights to advance the precision medicine of tomorrow," Centogene CEO Andrin Oswald said in a statement.
In June, Centogene partnered with Alector on a study to identify patients with frontotemporal dementia who have certain genetic mutations.